FDA
-
-
-
-
-
-
-
Aurinia To Present Supportive AURORA 2 Continuation Study Interim Analysis Demonstrating Long-Term Safety & Efficacy of LUPKYNIS™ (voclosporin) in Subjects with Lupus Nephritis
-
-
-
-
-
-
-
Aurinia Pharmaceuticals to Present at the Bloom Burton & Co. Healthcare Investor Conference
-
-
-
-
-
-
-
Aurinia Pharmaceuticals to Release Fourth Quarter and Year End 2020 Financial Results on February 24, 2021
-
-
-
-
-
-
-
Aurinia Pharmaceuticals to Present at the 2020 Jefferies Virtual London Healthcare Conference
-
-
-
-
-
-
-
Aurinia Pharmaceuticals Announces Launch of Lupus Nephritis Disease-State Awareness Initiative for Healthcare Professionals, TimeIsNephrons.com
-
-
-
-
-
-
-
Aurinia Pharmaceuticals (AUPH) Announces FDA Acceptance of Filing of NDA and Priority Review for Voclosporin for Treatment of Lupus Nephritis
-
-
-
-
-
-
-
Aurinia Completes Submission of New Drug Application to the U.S. Food & Drug Administration for Voclosporin for the Treatment of Lupus Nephritis
-
322,950 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

